TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Postoperative pneumothorax incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prolonged air-leakage incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of air leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median intensity of block discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of ondansetron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life (t1/2) of ondansetron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure rate (relapses plus withdrawals)
Endpoint domain: Mortality/survival
Primary endpoint: tolerability (side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: risk of ischemic cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: ∆Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Late infected hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Relief of nose blockage symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Mood Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptoms of Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of MRI for low-grade MEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of FNA for low-grade MEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: decrease in aggregate laboratory use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: instances of delayed diagnosis of acute kidney injury
Endpoint domain: Adverse events/effects
Primary endpoint: near misses reported
Endpoint domain: Adverse events/effects
Primary endpoint: long-lasting complications
Endpoint domain: Adverse events/effects
Primary endpoint: TAG incremental area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin incremental area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: beneficial effect of community pharmacist intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of emotional burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Voiding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NEI VFQ‐25 near activity score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NEI VFQ‐25 distance activity score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Little's irregularity index at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of MCP-1 and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of CRP and VCAM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of MMP-9 and IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvements in back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pain-related impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: return-to-work rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Wheal size response to extracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gains in leg press specific peak power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in physical violence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in psychological violence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in sexual violence rates
Endpoint domain: Adverse events/effects
Primary endpoint: PDA closure at 7 days after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NT-proBNP level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year local control
Endpoint domain: Mortality/survival
Primary endpoint: general quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reflux control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: troublesome daily dysphagia
Endpoint domain: Adverse events/effects
Primary endpoint: Passing the follow-up official predriving assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rated drug liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-rated drug wanting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-rated good drug effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: device-oriented composite end-point (DoCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Increase of plasma levels of GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean reduction in GI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: bacterial translocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastric colonisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct classification of subjects as RP or non-RP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the instruments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the instruments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen desaturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean tongue strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of seroprotection after challenge dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titer after challenge dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prolonged P-wave duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of atrial tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage time pH >4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiovascular variability (LF(nu)-DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 7 days PPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral and psychological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total BPRS symptoms of more than or equal to 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in avolition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in BPRS anxiety/depression factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cholesterol absorption index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol FSR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Task completion times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall performance ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Navigation/pushability ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Statistical power to detect risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: postoperative septic arthritis cases
Endpoint domain: Adverse events/effects
Primary endpoint: variability in SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: current SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: current DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in MCP-1/CCL2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in MIP-1alpha/CCL3 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in IL-1beta production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scheduling appointments at a VA addictions clinic within 60 days of jail release
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention in addictions treatment at 90 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of infective morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Satiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: H2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CH4 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: stage 3-4 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: self-administered ethanol refills
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with mean capillary glucose test <7 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infarct growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean postoperative Hospital for Special Surgery knee score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall incidents during bathroom visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life appreciation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Levels of anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physician disclosure of CAM use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cortical processing improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: response selection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: response variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Axis II comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of first attempt at intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: experimental sensory and pain testing parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scales for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically confirmed quit attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking dependence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slow Vital Capacity (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of Atelectasis
Endpoint domain: Adverse events/effects
Primary endpoint: JOA and VAS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days of absenteeism and presenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Household work days gained
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Participation in family, social and leisure activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: sensitivity for tumour remnant detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: confirmation of complete tumour removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: distance in the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleepiness at work
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Chromatic vision recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects considered improved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ADHD symptom checklist scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary diagnosis agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Exact system diagnosis agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physical examination findings agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IGF‐I and IGF‐II levels in amniotic fluid and maternal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth weights of the neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute care utilization after hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospital readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urine PGE-M levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall level of adherence to CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IRLS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with score decrease > or = 15 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with follow-up score < or = 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colonic decompression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone density at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of cervical CCR5CD4 cells, regulatory T cells, and tissue macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peripheral blood CD4 and CD8 T cells expressing markers of activation and trafficking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proliferation of PBMCs to the major cat allergen Fel d 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PRIMUS Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PRIMUS QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: U-FIS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: risk of primary outcome event
Endpoint domain: Mortality/survival
Primary endpoint: clearance over bioavailability (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: terminal half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total area under the serum concentration-time curve (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak 13CO2 excretion in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patent posterior choana
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choanal stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local progression free interval at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA for insulin resistance (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute insulin response of insulin (AIRins)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient satisfaction survey scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Direct and indirect costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Screening time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep infection
Endpoint domain: Adverse events/effects
Primary endpoint: mean patient glycated hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: general health improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fatigue decrease
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: level of agreement on revascularisation modality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported symptoms of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall substance use index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SOMCT scores after extubation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Need for antihypertensive medication postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Spectacle independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse symptoms (glare and haloes)
Endpoint domain: Adverse events/effects
Primary endpoint: exercise duration at 0.1 mV ST depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: double product at 0.1 mV ST depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity score using myocardial perfusion scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VPS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful reperfusion at procedure end
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable outcome (modified Rankin Scale score, 0‐2) at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of HAPUs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to injury survival analysis for HAPU development
Endpoint domain: Mortality/survival
Primary endpoint: mean telomerase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wound surface area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: plasma intercellular adhesion molecule-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensitive C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBV-DNA negativization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete response (normal ALT and negative HBV-DNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: G2+ lower GI toxicity-free rates
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative proportion of RTOG G2+ GI toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: RTOG G2+ bladder toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in LZC across time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Psychiatric Rating Scale for Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical health scores at 3 months after treatment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum 25(OH)D levels > 20 ng/mL in neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of hypertension (HTN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes